U.S., July 31 -- ClinicalTrials.gov registry received information related to the study (NCT07093203) titled 'Rezafungin Peritoneal Diffusion for Intra-abdominal Candidiasis' on July 22.
Brief Summary: ntra-abdominal candidiasis is a serious infection common in critically ill patients, often leading to high mortality if not treated quickly. Standard antifungal treatments may be less effective due to growing resistance and poor drug penetration into the abdominal cavity. In critically ill patients, drug levels can vary widely due to factors like surgery, inflammation, fluid resuscitation, or extracorporeal support, increasing the risk of underdosing. Rezafungin is a new antifungal agent with a long half-life and broad activity against Candid...